GlaxoSmithKline Pharmaceuticals share news and announcements
NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap
Formerly Glaxo (India)
Last close ₹2,404.70down ₹29.00 (1.19%)BSE ₹2,404.80
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,433.70.
52-week range of traded prices to 23 Oct 2026
₹2,088.10Low, 12 Jun 2026₹3,120.70High, 28 Aug 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹40,737 Cr221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 3 Aug 2026
- 38.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 13 May 2026
- 18.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.37%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 3 Aug 2026
- 50.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 3 Aug 2026
- 56.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 13 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 56,17458.6% delivered
GlaxoSmithKline Pharmaceuticals board meetings
114 filed, newest first. Page 3 of 3.
Feb 2010
3 Feb · Board meeting
Inter-alia, to consider amongst other things, approval of audited financial results for the year ended December 31, 2009 and to recommend dividend, if any, on the equity shares of the Company.
Oct 2009
15 Oct · Board meeting
Interalia, to consider amongst other things, approval of unaudited financial results for the 3rd quarter June-September 2009.
Jul 2009
15 Jul · Board meeting
Interalia, to consider amongst other things, approval of unaudited financial results for the 2nd Quarter April-June 2009 & Half year ended June 30, 2009.
Apr 2009
13 Apr · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended 31st March 2009
Feb 2009
11 Feb · Board meeting
To consider, amongst other things, approval of the audited financial results for the year ended December 31, 2008 and to recommend dividend, if any, on the equity shares of the Company.
Oct 2008
13 Oct · Board meeting
Inter alia, to consider amongst other things, approval of unaudited financial results for the 3rd quarter ended September 30, 2008.
Jul 2008
9 Jul · Board meeting
Inter alia, to consider amongst other things, approval of unaudited financial results for the quarter April - June 2008 (Q2) and half-year January - June 2008.
Apr 2008
1 Apr · Board meeting
Meeting on 21 Apr 2008: “Unaudited Financial Results for the qtr ended March 31, 2008”
Feb 2008
15 Feb · Board meeting
To consider, amongst other things, approval of the audited financial results for the year ended December 31, 2007 and to recommend dividend, if any, on the equity shares of the Company.
Oct 2007
12 Oct · Board meeting
To consider amongst other things, approval of unaudited financial results for the 3rd Quarter ended September 30, 2007.
Jul 2007
26 Jul · Board meeting
July 26, 2007 that: "At a Board Meeting of the Company held today, the Board of Directors has approved the divestment of the Company's Fine Chemical Business ("QFC Undertaking") as a going concern to Thermo Electron LLS India Private Limited, a subsidiary of Thermo Fisher Scientific Inc., a leading American Company, for a total consideration of Rs.240 crores, subject to receipt of necessary approvals. The proposed divestment of the QFC Undertaking will transfer all rights and obligations of the Company in the QFC Undertaking. The Company will now proceed seeking the approval of its shareholders through a postal ballot. Subject to receipt of the Shareholders' consent and other requisite approvals, the transaction is expected to be completed by end September 2007".6 Jul · Board meeting
To consider amongst other things, approval of unaudited financial results for the half-year ended June 30, 2007.
Apr 2007
11 Apr · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended March 31, 2007.
Feb 2007
12 Feb · Board meeting
To consider amongst other things, approval of the audited financial results for the year ended December 31,2006 and to recommend dividend, if any, on the equity shares of the Company.